Larimar Therapeutics, Inc. (LRMR) Dividend History

Larimar Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare and genetically defined diseases. The company utilizes its proprietary drug delivery platform to develop therapies targeting disorders such as Friedreich's ataxia and other neurodegenerative and metabolic conditions. Founded with an emphasis on innovative approaches to challenging diseases, Larimar aims to improve patient outcomes through novel therapeutic solutions.

Three Bala Plaza East. Suite 506, Bala Cynwyd, PA, 19004
Phone: 844-511-9056
Website: https://www.larimartx.com

Dividend History

Larimar Therapeutics, Inc. currently does not pay dividends

Company News

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Larimar Therapeutics, a clinical-stage biotechnology company, announced that data from its nomlabofusp studies will be presented at the International Congress for Ataxia Research. Nomlabofusp is a protein replacement therapy designed to address Friedreich's ataxia.

GlobeNewswire Inc.
2 Potentially High-Reward Growth Stocks to Buy Right Now

These two biotechnology stocks could be gearing up for a run.

The Motley Fool

Featured Companies: RNA
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics

Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.

Zacks Investment Research

Featured Companies: BIIB IONS PTCT
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News

Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.

Zacks Investment Research

Featured Companies: BIIB IONS PTCT
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study

The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.

Zacks Investment Research

Featured Companies: BIIB ENTX

Dividend data last updated 06/07/2025 06:37:40 UTC